Hedef ve Amaç
Prosigna test provides information about breast cancer prognosis with 50 different gene expressions. It provides information about the risk of recurrence of the disease within a 10-year period according to tumor size and nodal status and allows patients to be divided into three separate categories in terms of risk: low, intermediate and high.